We believe that there is significant value in Generx, based on the recognition of a growing body of safety and efficacy data from the clinical development of multiple gene therapy clinical studies now progressing forward worldwide, and the strategic valuations being placed on DNA-based biologic product candidates," said Chris Reinhard, Chief Executive Officer of Taxus
Element Stent is designed specifically for coronary stenting and leverages the performance advantages of the Element Stent platform with a decade of clinical success from the TAXUS
Our second-generation TAXUS
Liberte Stent launched earlier this month in Japan, and we look forward to introducing our third-generation Element(TM) Stent on both drug platforms.
stated that, "These results have also led us to conclude that the CYPHER([R]) Stent is clinically superior to bare-metal stents and the Taxus
Stent when the safety and effectiveness outcomes in this analysis are taken into account.
For more information about Taxus
Cardium's product development activities please visit http://www.
In a subgroup analysis of more than 1,100 patients with diabetes, who typically are sicker and have more challenging artery disease, XIENCE V demonstrated a numerically lower TLF rate compared to TAXUS
at one year (6.
Liberte Stent will replace the TAXUS
Express2 Stent, which was launched in Japan in May 2007.
In the trial's composite endpoint, XIENCE V demonstrated a clinically significant 30 percent risk reduction in TLF (target lesion failure) compared to TAXUS
The PERSEUS clinical program compares the TAXUS
Element Stent to prior-generation stents in more than 1,600 patients in two parallel trials at 90 centers worldwide.
Express Atom Stent will provide better options for U.
Additional clinical evidence of the combined efficacy of highly biocompatible and thromboresistant Carbofilm(TM) coating together with the "smart" drug Tacrolimus (a proven cytostatic drug, which selectively inhibits smooth muscle cells proliferation and migration, while permitting enhanced re-endothelialization of the stent) will be provided by the European clinical trial MASTER (Multicenter randomized clinical trial to evaluate JAnuS Flex Tacrolimus Eluting CaRbostent as compared to Taxus
Paclitaxel eluting stent in AMI patients).
In the Study, Patients Receiving XIENCE V Had a 77 Percent Lower Rate of Stent Thrombosis (Blood Clot) than TAXUS
Liberte at Two Years